Home Cart Sign in  
Chemical Structure| 1211540-92-9 Chemical Structure| 1211540-92-9

Structure of 1211540-92-9

Chemical Structure| 1211540-92-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 1211540-92-9 ]

CAS No. :1211540-92-9
Formula : C5H2BrClFN
M.W : 210.43
SMILES Code : FC1=CN=CC(Br)=C1Cl
MDL No. :MFCD18257571
InChI Key :DGAXTZFGBOIDAB-UHFFFAOYSA-N
Pubchem ID :70977219

Safety of [ 1211540-92-9 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 1211540-92-9 ] Show Less

Physicochemical Properties

Num. heavy atoms 9
Num. arom. heavy atoms 6
Fraction Csp3 0.0
Num. rotatable bonds 0
Num. H-bond acceptors 2.0
Num. H-bond donors 0.0
Molar Refractivity 36.91
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

12.89 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.82
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.27
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

3.06
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

2.28
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

3.17
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

2.52

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-3.07
Solubility 0.18 mg/ml ; 0.000855 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.18
Solubility 1.4 mg/ml ; 0.00665 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-3.78
Solubility 0.035 mg/ml ; 0.000166 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.97 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.7

Application In Synthesis of [ 1211540-92-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1211540-92-9 ]
  • Downstream synthetic route of [ 1211540-92-9 ]

[ 1211540-92-9 ] Synthesis Path-Upstream   1~2

  • 1
  • [ 407-20-5 ]
  • [ 1211540-92-9 ]
YieldReaction ConditionsOperation in experiment
89%
Stage #1: With n-butyllithium; diisopropylamine In tetrahydrofuran; hexane at -78 - -70℃; for 1 h;
Stage #2: With hexachloroethane In tetrahydrofuran; hexane at -78 - 20℃;
To a solution of diisopropylamine (6.899 g, 9.555 mL, 68.18 mmol) in THF (75 mL) cooled to -78°C, was added butyllithium (25 mL of 2.5 M in hexanes, 62.5 mmol). The reaction mixture was allowed to warm to -20°C then cooled back down to -78°C. A solution of 3-bromo-5-fluoro-pyridine (10 g, 56.82 mmol) in THF (25 mL) was added dropwise keeping temperature below -70°C (approx 30 mins). The reaction mixture was stirred at - 78°C for 30 min and a solution of 1, 1, 1,2,2,2-hexachloroethane (14.8 g, 62.5 mmol) in THF (20 niL) was then added dropwise, keeping temperature below -70°C (over approx 30 mins). The mixture was stirred at -78°C for 20 minutes, allowed to warm to room temperature, cooled back to 0°C and quenched with water (100 mL). EtOAc (400 mL) was then added, and organic layer separated, washed with water (2x), brine (lx), dried (MgS04), filtered and concentrated in vacuo to leave a brown solid. The solid was triturated in pentane (lOOmL) for10 minutes, then filtered. The filtrate was concentrated in vacuo to afford product as a brown011 that turned to a crystalline solid on standing, 11.85 g, 89percent). XH NMR (DMSO-d6) δ 8.78 (s, 1H), 8.76 (s, 1H). [00372] To a solution of 3-bromo-4-chloro-5-fluoro-pyridine (7.56 g, 32.18 mmol) in pentane (100 mL) was added hydrogen chloride (2M in ether) (17.7 mL of 2 M, 35.4 mmol). An off-white precipitate formed instantly. The mixture was stirred for 5 minutes then the solid was collected by filtration, washed with pentane and dried by suction to afford the desired product as an off-white solid (4.79 g, 60percent). XH NMR (DMSO-d6) δ 8.77 (s, 1H), 8.75 (s, 1H).
89%
Stage #1: With n-butyllithium; diisopropylamine In tetrahydrofuran; hexane at -78 - -70℃; for 1 h;
Stage #2: With hexachloroethane In tetrahydrofuran; hexane at -78 - -70℃; for 0.833333 h;
Preparation 10: (l-(3-amino-5-fluoropyridin-4-yl)piperidin-4-yl)(4-methylpiperazin-l- yl)methanone (hydrochloride) 17b Scheme 5 Step 1: 3-bromo-4-chloro-5-fluoropyridine hydrochloride 18 [00261] To a solution of diisopropylamine (6.899 g, 9.555 mL, 68.18 mmol) in THF (75 mL) cooled to -78°C, was added butyllithium (25 mL of 2.5 M in hexanes, 62.5 mmol). The reaction mixture was allowed to warm to -20°C then cooled back down to -78°C. A solution of 3-bromo-5-fluoro-pyridine (10 g, 56.82 mmol) in THF (25 mL) was added dropwise keeping temperature below -70°C (approx 30 mins). The reaction mixture was stirred at - 78°C for 30 min and a solution of 1, 1, 1,2,2,2-hexachloroethane (14.8 g, 62.5 mmol) in THF (20 mL) was then added dropwise, keeping temperature below -70°C (over approximately 30 mins). The mixture was stirred at -78°C for 20 minutes, allowed to warm to room temperature, cooled back to 0°C and quenched with water (100 rnL). EtOAc (400 mL) was then added, and organic layer separated, washed with water (2x), brine (lx), dried (MgS04), filtered and concentrated in vacuo to leave a brown solid. The solid was triturated in pentane (lOOmL) for 10 minutes, then filtered. The filtrate was concentrated in vacuo to afford product as a brown oil that turned to a crystalline solid on standing, 1 1.85 g, 89percent). lH NMR (DMSO-d6) δ 8.78 (s, 1H), 8.76 (s, 1H). [00262] To a solution of 3-bromo-4-chloro-5-fluoro-pyridine (7.56 g, 32.18 mmol) in pentane (100 mL) was added hydrogen chloride (2M in ether) (17.7 mL of 2 M, 35.4 mmol). An off-white precipitate formed instantly. The mixture was stirred for 5 minutes then the solid was collected by filtration, washed with pentane and dried by suction to afford the desired product as an off-white solid (4.79 g, 60percent). XH NMR (DMSO-d6) δ 8.77 (s, 1H), 8.75 (s, 1H).
89%
Stage #1: With n-butyllithium; diisopropylamine In tetrahydrofuran; hexane at -78 - -70℃; for 1 h;
Stage #2: With hexachloroethane In tetrahydrofuran; hexane at -78 - -70℃; for 0.833333 h;
Preparation 9: (l-(3-amino-5-fluoropyridin-4-yl)piperidin-4-yl)(4-methylpiperazin-l- yl)methanone (hydrochloride) 17 Scheme 4 Step 1: 3-bromo-4-chloro-5-fluoropyridine hydrochloride 18 [00264] To a solution of diisopropylamine (6.899 g, 9.555 mL, 68.18 mmol) in THF (75 mL) cooled to -78°C, was added butyllithium (25 mL of 2.5 M in hexanes, 62.5 mmol). The reaction mixture was allowed to warm to -20°C then cooled back down to -78°C. A solution of 3-bromo-5-fluoro-pyridine (10 g, 56.82 mmol) in THF (25 mL) was added dropwise keeping temperature below -70°C (approx 30 mins). The reaction mixture was stirred at - 78°C for 30 min and a solution of 1, 1, 1,2,2,2-hexachloroethane (14.8 g, 62.5 mmol) in THF (20 mL) was then added dropwise, keeping temperature below -70°C (over approx 30 mins). The mixture was stirred at -78°C for 20 minutes, allowed to warm to room temperature, cooled back to 0°C and quenched with water (100 mL). EtOAc (400 mL) was then added, and organic layer separated, washed with water (2x), brine (lx), dried (MgS04), filtered and concentrated in vacuo to leave a brown solid. The solid was triturated in pentane (lOOmL) for 10 minutes, then filtered. The filtrate was concentrated in vacuo to afford product as a brown 011 that turned to a crystalline solid on standing, 11.85 g, 89percent). 1H NMR (DMSO-d6) δ 8.78 (s, 1H), 8.76 (s, 1H). [00265] To a solution of 3-bromo-4-chloro-5-fluoro-pyridine (7.56 g, 32.18 mmol) in pentane (100 mL) was added hydrogen chloride (2M in ether) (17.7 mL of 2 M, 35.4 mmol). An off-white precipitate formed instantly. The mixture was stirred for 5 minutes then the solid was collected by filtration, washed with pentane and dried by suction to afford the desired product as an off-white solid (4.79 g, 60percent). 1H NMR (DMSO-d6) δ 8.77 (s, 1H), 8.75 (s, 1H).
89%
Stage #1: With n-butyllithium; diisopropylamine In tetrahydrofuran; hexane at -78 - -70℃; for 1 h;
Stage #2: With hexachloroethane In tetrahydrofuran; hexane at -78 - -70℃; for 0.833333 h;
To a solution of diisopropylamine (6.899 g, 9.555 mL, 68.18 mmol) in THF (75 mL) cooled to -78°C, was added butyllithium (25 mL of 2.5 M in hexanes, 62.5 mmol). The reaction mixture was allowed to warm to -20°C then cooled back down to -78°C. A solution of 3-bromo-5-fluoro-pyridine (10 g, 56.82 mmol) in THF (25 mL) was added dropwise keeping temperature below -70°C (approx 30 mins). The reaction mixture was stirred at - 78°C for 30 mm and a solution of 1,1,1,2,2,2-hexachloroethane (14.8 g, 62.5 mmol) in THF (20 mL) was then added dropwise, keeping temperature below -70°C (over approx 30 mins). The mixture was stirred at -78°C for 20 minutes, allowed to warm to room temperature, cooled back to 0°C and quenched with water (100 mL). EtOAc (400 mL) was then added, and organic layer separated, washed with water (2x), brine (lx), dried (Mg504), filtered and concentrated in vacuo to leave a brown solid. The solid was triturated in pentane (lOOmL) for 10 minutes, then filtered. The filtrate was concentrated in vacuo to afford product as a brown oil that turned to a crystalline solid on standing, 11.85 g, 89percent). ‘H NMR (DMSO-d6) ö 8.78 (s, 1H), 8.76 (s, 1H).
89%
Stage #1: With n-butyllithium; diisopropylamine In tetrahydrofuran; hexane at -78 - -70℃; for 1 h;
Stage #2: With hexachloroethane In tetrahydrofuran; hexane at -78 - -70℃; for 0.833333 h;
To a solution of diisopropylamine (6.899 g, 9.555 mL, 68.18 mmol) in THF (75 mL) cooled to -78° C., was added butyllithium (25 mL of 2.5 M in hexanes, 62.5 mmol).
The reaction mixture was allowed to warm to -20° C. then cooled back down to -78° C. A solution of 3-bromo-5-fluoro-pyridine (10 g, 56.82 mmol) in THF (25 mL) was added dropwise keeping temperature below -70° C. (approx 30 mins).
The reaction mixture was stirred at -78° C. for 30 min and a solution of 1,1,1,2,2,2-hexachloroethane (14.8 g, 62.5 mmol) in THF (20 mL) was then added dropwise, keeping temperature below -70° C. (over approx 30 mins).
The mixture was stirred at -78° C. for 20 minutes, allowed to warm to room temperature, cooled back to 0° C. and quenched with water (100 mL). EtOAc (400 mL) was then added, and organic layer separated, washed with water (2*), brine (1*), dried (MgSO4), filtered and concentrated in vacuo to leave a brown solid.
The solid was triturated in pentane (100 mL) for 10 minutes, then filtered.
The filtrate was concentrated in vacuo to afford product as a brown oil that turned to a crystalline solid on standing, 11.85 g, 89percent).
1H NMR (DMSO-d6) δ 8.78 (s, 1H), 8.76 (s, 1H).
70% With lithium diisopropyl amide In tetrahydrofuran; hexachloroethane at -78 - 20℃; for 2.25 h; To a solution of LDA (2.0 mol/L THF solution, 8.9 mL, 18 mmol) in THF (45 mL) which was cooled to -78°Cwas added dropwise a solution of compound (VII-16) (2.60 g, 14.8 mmol) in THF (12 mL), and the mixture was stirredat -78°C for 45 min. To the reaction mixture was added dropwise a solution of hexachloroethane (3.85 g, 16.3 mmol) inTHF (12 mL), and the mixture was stirred at -78°C for 30 min, warmed to room temperature and stirred for 1 hr. Thereaction was discontinued by adding saturated aqueous ammonium chloride solution, and the mixture was extractedwith ethyl acetate. The organic layer was washed successively with saturated aqueous ammonium chloride solution andsaturated brine, and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, andthe residue was purified by silica gel column chromatography (n-hexane:ethyl acetate = 97:3 →85:15) to give compound(VII-17) (yield 2.18 g, 70percent) as a pale-yellow solid
70%
Stage #1: With lithium diisopropyl amide In tetrahydrofuran at -78℃; for 0.75 h;
Stage #2: With hexachloroethane In tetrahydrofuran at -78 - 20℃; for 1.5 h;
LDA (2.0 mol / L THF solution cooled to -78 ° C.,8.9 mL, 18 mmol) in THF (45 mL)Compound (VII-16) (2.60 g, 14.8 mmol)In THF (12 mL) was added dropwise,And the mixture was stirred at -78 ° C. for 45 minutes.A solution of hexachloroethane (3.85 g, 16.3 mmol) in THF (12 mL) was added dropwise to the reaction solution,After stirring at -78 ° C. for 30 minutes,The mixture was warmed to room temperature and stirred for 1 hour.A saturated aqueous solution of ammonium chloride was added to stop the reaction, followed by extraction with ethyl acetate.The organic layer was washed with a saturated aqueous ammonium chloride solution,And then washed successively with saturated brine,And dried over anhydrous sodium sulfate.The solvent was distilled off under reduced pressure,The residue was purified by silica gel column chromatography (n-hexane: ethyl acetate = 97: 3 → 85: 15)To give Compound (VII-17)(Yield 2.18 g, Yield 70percent)As a pale yellow solid.

References: [1] Patent: WO2014/89379, 2014, A1, . Location in patent: Paragraph 00371; 00372.
[2] Patent: WO2014/143240, 2014, A1, . Location in patent: Paragraph 00260-00261.
[3] Patent: WO2014/143242, 2014, A1, . Location in patent: Paragraph 00263-00264.
[4] Patent: WO2015/84384, 2015, A1, . Location in patent: Paragraph 00243.
[5] Patent: US2015/158868, 2015, A1, . Location in patent: Paragraph 0309; 0310.
[6] Patent: EP3351533, 2018, A1, . Location in patent: Paragraph 0282; 0283.
[7] Patent: JP2018/145180, 2018, A, . Location in patent: Paragraph 0283; 0284; 0285.
[8] Patent: WO2012/148808, 2012, A1, . Location in patent: Page/Page column 54.
[9] Patent: US2015/158872, 2015, A1, .
  • 2
  • [ 1613192-96-3 ]
  • [ 1211540-92-9 ]
YieldReaction ConditionsOperation in experiment
41 g With sodium hydroxide In dichloromethane for 1 h; Cooling with ice [ 0505] 3 -bromo-4-chloro-5-fluoro-pyridine hydrochloride18 ( 62 g, 251.1 mmol) was suspended in DCM ( 600 mL) andstirred. The mixture was cooled in an ice bath and sodiumhydroxide (276.2 mL of 1 M, 276.2 mmol) was added slowly.The resulting mixture was stirred for 1 hour. The mixture wasphase-separated. More DCM/water was added to aid phaseseparation. Some tarry particulates remained in the aqueousphase. The organic phase was washed with brine, dried(MgS04 ), filtered and concentrated. The residue was trituratedwith heptane. The heptane solution was filtered througha florsil pad, eluting with heptane. The filtrate was concentratedto an oil which solidified. This gave 41 g offree base.
References: [1] Patent: US2015/158872, 2015, A1, . Location in patent: Paragraph 0503; 0505.
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 1211540-92-9 ]

Fluorinated Building Blocks

Chemical Structure| 884494-36-4

A123345 [884494-36-4]

3-Bromo-2-chloro-5-fluoropyridine

Similarity: 0.76

Chemical Structure| 1211590-18-9

A444339 [1211590-18-9]

4-Bromo-3-chloro-5-fluoropyridine

Similarity: 0.74

Chemical Structure| 189281-48-9

A198750 [189281-48-9]

2,4-Dichloro-5-fluoropyridine

Similarity: 0.72

Chemical Structure| 851386-40-8

A257956 [851386-40-8]

4-Chloro-2,5-difluoropyridine

Similarity: 0.72

Chemical Structure| 1260843-59-1

A179968 [1260843-59-1]

3,4-Dibromo-5-fluoropyridine

Similarity: 0.71

Bromides

Chemical Structure| 181256-18-8

A118117 [181256-18-8]

3-Bromo-4-chloropyridine hydrochloride

Similarity: 0.78

Chemical Structure| 884494-36-4

A123345 [884494-36-4]

3-Bromo-2-chloro-5-fluoropyridine

Similarity: 0.76

Chemical Structure| 1211590-18-9

A444339 [1211590-18-9]

4-Bromo-3-chloro-5-fluoropyridine

Similarity: 0.74

Chemical Structure| 1260843-59-1

A179968 [1260843-59-1]

3,4-Dibromo-5-fluoropyridine

Similarity: 0.71

Chemical Structure| 1001056-83-2

A151063 [1001056-83-2]

3-Bromo-4,5-dichloropyridine

Similarity: 0.70

Chlorides

Chemical Structure| 181256-18-8

A118117 [181256-18-8]

3-Bromo-4-chloropyridine hydrochloride

Similarity: 0.78

Chemical Structure| 884494-36-4

A123345 [884494-36-4]

3-Bromo-2-chloro-5-fluoropyridine

Similarity: 0.76

Chemical Structure| 1211590-18-9

A444339 [1211590-18-9]

4-Bromo-3-chloro-5-fluoropyridine

Similarity: 0.74

Chemical Structure| 189281-48-9

A198750 [189281-48-9]

2,4-Dichloro-5-fluoropyridine

Similarity: 0.72

Chemical Structure| 851386-40-8

A257956 [851386-40-8]

4-Chloro-2,5-difluoropyridine

Similarity: 0.72

Related Parent Nucleus of
[ 1211540-92-9 ]

Pyridines

Chemical Structure| 181256-18-8

A118117 [181256-18-8]

3-Bromo-4-chloropyridine hydrochloride

Similarity: 0.78

Chemical Structure| 884494-36-4

A123345 [884494-36-4]

3-Bromo-2-chloro-5-fluoropyridine

Similarity: 0.76

Chemical Structure| 1211590-18-9

A444339 [1211590-18-9]

4-Bromo-3-chloro-5-fluoropyridine

Similarity: 0.74

Chemical Structure| 189281-48-9

A198750 [189281-48-9]

2,4-Dichloro-5-fluoropyridine

Similarity: 0.72

Chemical Structure| 851386-40-8

A257956 [851386-40-8]

4-Chloro-2,5-difluoropyridine

Similarity: 0.72